The global Recombinant Erythropoietin Market is estimated to be valued at US$7.01 billion in 2023 and is expected to exhibit a CAGR of 2% over the forecast period of 2023-2030, according to a new report published by Coherent Market Insights.
Recombinant erythropoietin, a hormone responsible for stimulating red blood cell production, has gained significant popularity due to its application in treating various diseases such as anemia caused by chronic kidney disease and cancer chemotherapy. Its ability to enhance endurance and improve performance in athletes has also driven its demand in the sports industry.
However, the market also faces challenges such as the high cost of recombinant erythropoietin therapy and the availability of alternatives in certain regions. Despite these obstacles, the market is expected to witness substantial growth due to increasing prevalence of anemia and greater awareness regarding the therapeutic benefits of erythropoietin.
Market Key Trends:
One key trend driving the growth of the Recombinant Erythropoietin Market is the rising popularity of biosimilars. Biosimilars are biologic products that are highly similar to and have no clinically meaningful differences from an existing FDA-approved reference product. They provide a cost-effective alternative to expensive brand-name erythropoietin products.
For example, Amgen Inc., a key player in the market, offers biosimilar versions of their original erythropoietin drugs, such as Epogen and Aranesp. These biosimilars have gained significant traction due to their comparable efficacy and lower cost, making them an attractive option for healthcare providers and patients.
The Recombinant Erythropoietin Market is segmented based on the application. One of the major segments contributing a large share to the market is the treatment of anemia caused by chronic kidney disease (CKD).
CKD is a serious health condition that affects millions of people worldwide. It leads to a decrease in the production of erythropoietin by the kidneys, resulting in anemia. Recombinant erythropoietin is widely used for treating anemia in CKD patients as it stimulates the production of red blood cells, thereby improving their quality of life.
Within the CKD segment, sub-segment dominating the market is the end-stage renal disease (ESRD). ESRD refers to the final stage of CKD, where the kidneys are no longer able to function properly and require dialysis or kidney transplantation. This sub-segment dominates the market due to the higher prevalence of anemia in ESRD patients and the continuous need for erythropoietin therapy.
Market size related content:
The global Recombinant Erythropoietin Market Growth is expected to witness high growth, exhibiting a CAGR of 2% over the forecast period. This growth is driven by increasing prevalence of anemia caused by chronic kidney disease and cancer chemotherapy. Additionally, the rising popularity of biosimilars is expected to contribute to market expansion.
Regional analysis related content:
North America is expected to be the fastest growing and dominating region in the global Recombinant Erythropoietin Market. This can be attributed to the high prevalence of chronic kidney disease and cancer in this region, coupled with advanced healthcare infrastructure and favorable reimbursement policies.
Key players related content:
Key players operating in the global Recombinant Erythropoietin Market include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Roche Holding AG, Novartis AG, Biocon Limited, Teva Pharmaceutical Industries Ltd., LG Chem Ltd., Sandoz International GmbH (a subsidiary of Novartis AG), Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Celltrion Inc., 3SBio Inc., CJ CheilJedang Corporation, and BioSidus SA. These companies are actively engaged in research and development activities to introduce innovative erythropoietin products and biosimilars in the market.
The global Recombinant Erythropoietin Market is expected to witness significant growth driven by the rising demand for erythropoietin in the treatment of anemia caused by chronic kidney disease. The market is also influenced by key trends such as the popularity of biosimilars. North America is projected to be the fastest growing region, and key players are continually investing in research and development to introduce advanced erythropoietin products.